Last $0.29 USD
Change Today -0.0098 / -3.27%
Volume 23.3K
INSV On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

insite vision inc (INSV) Snapshot

Open
$0.30
Previous Close
$0.30
Day High
$0.30
Day Low
$0.29
52 Week High
07/14/14 - $0.35
52 Week Low
06/3/14 - $0.10
Market Cap
38.3M
Average Volume 10 Days
87.8K
EPS TTM
$0.03
Shares Outstanding
132.0M
EX-Date
--
P/E TM
10.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for INSITE VISION INC (INSV)

insite vision inc (INSV) Related Bloomberg News

View More Bloomberg News

insite vision inc (INSV) Related Businessweek News

No Related Businessweek News Found

insite vision inc (INSV) Details

InSite Vision Incorporated, an ophthalmic product development company, develops ophthalmic pharmaceutical products to address unmet eye care needs in the United States. It is developing products based on its proprietary DuraSite drug delivery technology. The company’s lead products comprise AzaSite, a macrolide antibiotic for the treatment of bacterial conjunctivitis; and Besivance, a fluoroquinolone antibiotic for the treatment of bacterial conjunctivitis. Its products also include ISV-101, a formulation with a low concentration of bromfenac for the treatment of dry eye disease. In addition, the company is involved in preparing a new drug application for the commercial approval of BromSite by the U.S. Food & Drug Administration for the prevention of pain and inflammation associated with ocular surgery; and advancing AzaSite Plus and DexaSite through Phase III clinical studies for the treatment of eye infections. Further, it has a pipeline of earlier-stage product candidates based on its platform technologies. The company has collaborative, licensing, and service agreements with Pfizer and Pfizer Products, Inc.; Akorn Pharmaceuticals; Catalent Pharma Solutions; and Bausch and Lomb Incorporated. InSite Vision Incorporated was founded in 1986 and is based in Alameda, California.

31 Employees
Last Reported Date: 03/31/14
Founded in 1986

insite vision inc (INSV) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $380.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $264.2K
Vice President of Operations and Quality
Total Annual Compensation: $236.3K
Chief Medical Officer, Vice President of Clin...
Total Annual Compensation: $347.3K
Vice President of Development and Secretary
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2013.

insite vision inc (INSV) Key Developments

InSite Vision Incorporated Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014

InSite Vision Incorporated reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. Revenues for the second quarter of 2014 were $6.3 million compared to $19.2 million for the same period in 2013. In the second quarter of 2014, revenues included a $6.0 million payment for the amendment to the Akorn License and royalties for net sales of AzaSite of $0.3 million. In the second quarter of 2013, revenues included $14.5 million for the sale of Besivance royalty rights and royalties for net sales of AzaSite of $4.7 million. Net income for the second quarter of 2014 was $37.1 million, or $0.28 per diluted share, compared to net income of $12.1 million, or $0.09 per diluted share, in the second quarter of 2013. In the second quarter of 2014, InSite recorded a gain of $36.0 million on the extinguishment of the AzaSite Notes. Income from operations was $2,256,000 against $13,972,000 for the same period of last year. The company announced that usage of cash in the second quarter was $2.9 million, which reflects the $6 million payment the company made to purchase the AzaSite debt, offset in part by $3.1 million of positive cash flows from operations in the quarter. For the six months, revenues were $7,502,000 against $24,500,000 for the same period of last year. Loss from operations was $1,216,000 against income of $14,327,000 for the same period of last year. Net income was $32,470,000 against $10,195,000 for the same period of last year. Net income per diluted share was $0.25 against $0.08 for the same period of last year.

InSite Vision Incorporated to Report Q2, 2014 Results on Aug 13, 2014

InSite Vision Incorporated announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 13, 2014

InSite Vision Incorporated, Q2 2014 Earnings Call, Aug 13, 2014

InSite Vision Incorporated, Q2 2014 Earnings Call, Aug 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSV:US $0.29 USD -0.0098

INSV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $163.68 USD +1.57
Johnson & Johnson $103.73 USD +0.78
Pfizer Inc $29.39 USD +0.01
View Industry Companies
 

Industry Analysis

INSV

Industry Average

Valuation INSV Industry Range
Price/Earnings 1.4x
Price/Sales 3.0x
Price/Book NM Not Meaningful
Price/Cash Flow 1.4x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSITE VISION INC, please visit www.insitevision.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.